XNK Therapeutics has announced that Ted Fjällman, Partner at Flerie Invest, has joined the company’s board of directors.
Flerie Invest led the SEK 132 million financing of XNK earlier this year by placing SEK 100 million and thus gaining approximately 22 percent of the total number of shares and votes in the company, becoming XNK’s largest shareholder.
“We are very happy to welcome Ted Fjällman as new board member. With his solid life science background, he will add valuable expertise and experience to the board,” says XNK’s chairman of the board Gunnar Mattsson.
Ted Fjällman is Partner at Flerie Invest, a European biotech and pharma investor managing a portfolio of more than 25 companies in the US, UK, Sweden, the Netherlands and other countries. Ted has been CEO and board member of several biotech companies engaged in a wide range of areas including immunology, oncology and biologics development and manufacturing, describes XNK Therapeutics.
He holds a Ph.D. in Biotechnology and Immunology from the University of Guelph, Canada, and splits his time between the UK, Sweden, and Switzerland.
“XNK is at the forefront of NK-cell therapy development because it has built a team of experts to manufacture cell therapies and to run clinical trials in this challenging but very promising area. I’m very excited to join the board!”, says Ted Fjällman.